Immunotherapy—which activates the body’s own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment. Fibrolamellar carcinoma primarily affects children and young adults and accounts for up to 2% of all liver cancers. It currently has no cure and has often metastasized by the time it is detected, leaving patients with a short life expectancy.
This article was originally published on MedicalXpress.com
